Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The INO news feed on Stock Titan aggregates company-issued press releases, regulatory updates, and other market-moving disclosures so readers can follow how INOVIO’s DNA medicine programs progress over time.
A major focus of recent INOVIO news is INO-3107, an investigational DNA medicine for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract. Updates include completion of a rolling Biologics License Application (BLA), FDA acceptance of the BLA for review under a Standard classification, and discussion of the accelerated approval pathway. News items also highlight clinical data showing reductions in the number of surgeries required by trial participants and long-term durability results from retrospective analyses.
Investors can also find announcements on capital-raising transactions, such as underwritten public offerings of common stock and warrants disclosed in Form 8-K filings and related press releases. INOVIO frequently reports on financial results, including quarterly earnings releases, as well as corporate governance and compensation matters like inducement stock option grants under its Inducement Plan.
Additional coverage includes scientific and clinical milestones, such as publication of Phase 1 proof-of-concept data for DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine and preclinical progress in DNA-encoded protein (DPROT) programs. Conference participation and investor events are also regular topics. For followers of INO stock, this news page offers a centralized view of the company’s clinical, regulatory, financial, and strategic communications.
INOVIO (NASDAQ: INO) announced that Phase 1 proof-of-concept DMAb data for COVID-19 were published in Nature Medicine on Oct 21, 2025.
Key findings: all 39 participants maintained biologically relevant DMAb levels through week 72, expressed antibodies bound SARS-CoV-2 Spike and neutralized pseudovirus, and no anti-drug antibodies were detected across ~1,000 blood samples. DMAbs were well tolerated; most adverse events were mild, temporary injection-site reactions and no SAEs were linked to the study drug. Investigators continue exploratory sample analyses.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced an equity grant under its 2022 Inducement Plan to a newly hired employee. The Compensation Committee approved a stock option award to purchase 1,302 shares of common stock with an exercise price of $2.34 per share, effective September 30, 2025.
The stock option will vest over three years, with one-third of shares vesting annually on the grant date anniversary. Vesting is contingent upon continued employment with INOVIO.
INOVIO (NASDAQ: INO), a biotechnology company, has announced its participation in multiple upcoming scientific conferences to present data on its lead product candidate INO-3107 for Recurrent Respiratory Papillomatosis (RRP) and next-generation DNA medicine technology.
The company has initiated a rolling Biologics License Application (BLA) submission for INO-3107, with plans to complete the submission in H2 2025 and targeting FDA file acceptance by year-end. The presentations will take place across various conferences including the American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe, and ESMO Congress.
Additionally, INOVIO will present the first preclinical data on DNA-encoded protein technology (DPROT) for Hemophilia A and showcase developments in DNA-encoded monoclonal antibody (DMAb) technology.
INOVIO (NASDAQ: INO) announced FDA's agreement to their rolling submission timeline for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company plans to complete the BLA submission in the coming months and will request priority review, targeting FDA file acceptance by the end of 2025.
The treatment has received Breakthrough Therapy designation and INOVIO is actively engaging with the FDA to expedite the approval process. The company believes INO-3107 could become the preferred treatment option for RRP patients and healthcare providers.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, will participate in the H.C. Wainwright 27th Annual Global Investment Conference.
The company will provide a pre-recorded presentation available on demand starting September 5, 2025, at 7:00 AM ET. INOVIO's management team will conduct in-person one-on-one meetings with investors during the conference. The webcast will remain accessible for 90 days through the provided link and INOVIO's Investor Relations Events page.
INOVIO (NASDAQ: INO) reported its Q2 2025 financial results and provided key business updates. The company is on track to submit a Biologics License Application (BLA) for INO-3107 in the second half of 2025, targeting FDA file acceptance by year-end. The company completed design verification testing of CELLECTRA® 5PSP device and requested rolling submission from FDA.
Financial highlights include a reduced net loss of $23.5 million ($0.61 per share) compared to $32.2 million in Q2 2024. R&D expenses decreased to $14.5 million from $23.1 million, and G&A expenses reduced to $8.6 million from $10.2 million. The company raised $22.5 million through a public offering in July 2025, with total cash position of $47.5 million as of June 30, 2025.
Clinical data for INO-3107 showed impressive results, with 86% of patients experiencing 50-100% reduction in surgeries by Year 2, and 50% achieving complete response. The company expects potential commercial launch in 2026 pending FDA approval.
INOVIO (NASDAQ: INO) published promising long-term data in The Laryngoscope for its DNA medicine INO-3107 in treating Recurrent Respiratory Papillomatosis (RRP). The retrospective study showed significant improvements in patient outcomes, with the Overall Response Rate increasing to 86% in Year 2 from 72% in Year 1, and Complete Response rate rising to 50% from 28%.
The mean number of required surgeries decreased substantially from 4.1 per year pre-treatment to 1.7 in Year 1 and 0.9 in Year 2. The study followed 28 patients with a median follow-up of 2.8 years, demonstrating continued improvement trends into Year 3. Importantly, INO-3107 was well-tolerated with no serious adverse events reported.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancers, and infectious diseases, will release its Q2 2025 financial results on August 12, 2025 after market close.
The company will host a conference call and webcast at 4:30 p.m. ET the same day, featuring a general business update and analyst Q&A session. Investors can access the live webcast through INOVIO's investor relations website, with a replay available for 90 days post-event.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the upcoming Orphan Drug Summit in Boston, Massachusetts. The company will present on July 16 at 4:30 PM ET, focusing on their DMAb Technology and its transformational potential in rare disease treatment.
The presentation will explore the capabilities of next generation DNA medicine technology in addressing rare diseases, as part of a conference that brings together industry leaders and innovators to discuss technological and manufacturing advancements in the rare disease space.
INOVIO Pharmaceuticals (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has announced the pricing of a $25 million public offering. The offering consists of 14,285,715 shares of common stock along with Series A and Series B warrants, all priced at $1.75 per share.
The warrants allow holders to purchase up to an additional 14,285,715 shares each at an exercise price of $1.75. The underwriters, led by Piper Sandler & Co., have a 30-day option to purchase up to 2,142,857 additional shares and corresponding warrants. The offering is expected to close around July 7, 2025.
FAQ
What is the current stock price of Inovio Pharmaceu (INO)?
What is the market cap of Inovio Pharmaceu (INO)?
